PER

2.47%

7.9¢ percheron therapeutics limited

Ann: ATL1102 DMD Clinical Trial Application Submitted in Europe, page-4

First 4 Last

Share
Profile

Follow
arjay

3,692 Posts.

827

13/07/22

09:40

Post #: 62508391
Share

Originally posted by Wise_One ↑

Well there you go - that explains why it's been getting hammered lately

In parallel the Company has been extensively evaluating its clinical plans for ATL1102 in DMD with the
focus on deploying its existing cash reserves in the most effective manner, to reduce upfront capital
requirements and extend its cash runway. The Company believes this capital management focus,
including the review of financing requirements and options for sourcing future funding (as and when
required), to be prudent given the present challenging market conditions.

The Company remains committed to its DMD program and to initiating the next clinical trial of ATL1102
in DMD as soon as possible to advance its clinical development for the benefit of the patients with
DMD and the broader Duchenne community.

In a nutshell, this tells the market imo:
- They need more money
- They're waiting for markets to turn to get more money
- They've delayed the trial
- There's now no visible timeline to the start of the trial as they say "as soon as possible" which in ANP's terms could be a very long time imo

To say I'm disappointed is an understatement and again, this all comes back to the CR at 24c that was undertaken - they should have done the complete amount they required in an insto/HNW placement so they guaranteed all the funds!

Baggies will spin today's news in to a positive, but as a realist, this just means more delays & they've told the mkt they're in cash preservation mode so they're also looking to raise money imo

Expand

Well not sure why you assume they have delayed the trial...if that was the case why put an application in Germany?

Delay the whole thing....imo

As it's only 9 countries with some 20 trial sites, so we have started....

$$ yes it's needed and we all know that...and he said he can't find some...agree on that...

ANP Price at posting: 8.3¢ Sentiment: Buy Disclosure: Held
3 Upvote

1 Great analysis

Reply

Top Stories

Bitcoin hits fresh record as instos pile into BTC ETFs – and Trump helps, too

Week 44 Wrap: Relatively boring week ahead of US election; HotCopper's most watched; Oz inflation at 3.5%

The Altcoin Landscape (Part 1): Key alternative cryptocurrencies to watch

MIN

Movers and Shakers: Zip Co, MinRes, Kuniko, more – The week's top ASX gainers

DXB

Dimerix links up with US NEPTUNE network to boost recruitment for FSGS study

Palladium's the newest geopolitical hot commodity. But ASX exposure is limited

'We're looking': Nickel-rich Indonesia sounds graphite warning to Aus producers

Making money: How many microcaps should be in an investor's portfolio?

Aussie inflation seemingly hit a 3 year low. So why's the ASX200 red?

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

There are more pages in this discussion • 90 more messages in this thread...

First 4 Last

Add PER (ASX) to my watchlist

(20min delay)
Last 7.9¢		Change -0.002(2.47%)		Mkt cap ! $81.90M

Open	High	Low	Value	Volume
8.0¢	8.0¢	7.9¢	$230.1K	2.904M

Buyers (Bids)

No.	Vol.	Price($)
1	51000	7.9¢

Sellers (Offers)

Price($)	Vol.	No.
8.0¢	163520	2

View Market Depth

No.	Vol.	Price($)
1	51000	0.079
18	1244001	0.078
10	1037506	0.077
9	894271	0.076
10	1100649	0.075

Price($)	Vol.	No.
0.080	163520	2
0.081	344626	2
0.082	150000	1
0.083	368750	3
0.084	200000	1

Last trade - 15.57pm 01/11/2024 (20 minute delay)

PER (ASX) Chart

Ann: ATL1102 DMD Clinical Trial Application Submitted in Europe, page-4

Bitcoin hits fresh record as instos pile into BTC ETFs – and Trump helps, too

Week 44 Wrap: Relatively boring week ahead of US election; HotCopper's most watched; Oz inflation at 3.5%

The Altcoin Landscape (Part 1): Key alternative cryptocurrencies to watch

Movers and Shakers: Zip Co, MinRes, Kuniko, more – The week's top ASX gainers

Dimerix links up with US NEPTUNE network to boost recruitment for FSGS study

Palladium's the newest geopolitical hot commodity. But ASX exposure is limited

'We're looking': Nickel-rich Indonesia sounds graphite warning to Aus producers

Making money: How many microcaps should be in an investor's portfolio?

Aussie inflation seemingly hit a 3 year low. So why's the ASX200 red?

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: ATL1102 DMD Clinical Trial Application Submitted in Europe, page-4

Top Stories

Bitcoin hits fresh record as instos pile into BTC ETFs – and Trump helps, too

Week 44 Wrap: Relatively boring week ahead of US election; HotCopper's most watched; Oz inflation at 3.5%

The Altcoin Landscape (Part 1): Key alternative cryptocurrencies to watch

Movers and Shakers: Zip Co, MinRes, Kuniko, more – The week's top ASX gainers

Dimerix links up with US NEPTUNE network to boost recruitment for FSGS study

Palladium's the newest geopolitical hot commodity. But ASX exposure is limited

'We're looking': Nickel-rich Indonesia sounds graphite warning to Aus producers

Making money: How many microcaps should be in an investor's portfolio?

Aussie inflation seemingly hit a 3 year low. So why's the ASX200 red?

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News